AstraZeneca in Talks to Shift Coronavirus Vaccine Production to Catalent’s Maryland Factory
AstraZeneca is reportedly in talks to shift production of its coronavirus vaccine to a Maryland-based factory operated by Catalent, Inc.
The New York Times reported that the British drugmaker is in negotiations with the federal government to to retrofit a production line after embattled drugmaker Emergent BioSolutions was forced to stop manufacturing the vaccine at a plant in Baltimore.
AstraZeneca was awarded a $1.2 billion contract last May from the federal government for clinical trials and for production of 300 million doses of the vaccine.
A federal official told The Times that the government was negotiating its contract to shift production of the vaccine from Emergent to Catalent.
Catalent currently produces AstraZenca’s vaccine for export.
Holly Campbell, a spokeswoman for AstraZeneca told The Times “we can confirm we are working with Catalent but have not disclosed specific details on supply.” A spokesperson for Catalent declined to comment to the newspaper.
Click here to read more via The Hill.
Latest posts by BioBuzz Media (see all)
- Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders - June 10, 2021
- Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases - June 10, 2021
- Judy Costello Appointed as Special Projects Manager, Office of the County Executive at Montgomery County, Maryland - June 10, 2021
- Montgomery County, University System of Maryland, and Montgomery College Sign Memorandum of Understanding to Expand County’s Leadership Role in Life and Regulatory Sciences Education and Innovation - June 9, 2021
- Rockville’s NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 and Opdivo® - June 8, 2021